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Abstract 
Background: Cardiovascular disease (CVD) is a major cause of shortened longevity in individuals 
with type 1 diabetes. Dyslipidemia is one of the important modifiable risk factors.  
Aim: To investigate different aspects of dyslipidemia in type 1 diabetes: Assess available lipid variables 
as markers of CVD risk in type 1 diabetes. Investigate association between lipid-lowering therapy 
(LLT) and CVD in primary prevention. Assess the adherence to LLT and the associations between non-
adherence and CVD risk. Investigate reasons for non-adherence from a sociodemographic perspective. 
Method: Clinical characteristics and laboratory measures were collected from the Swedish National 
Diabetes Register alongside with data from several other Swedish registries on health and 
socioeconomy. In study I Cox regression analyses were performed to assess LDL cholesterol and total 
cholesterol to HDL-cholesterol ratio as predictors of CVD in type 1 diabetes. In study II we investigated 
the association between primary prevention with LLT and the risk of CVD in 24,230 individuals with 
type 1 diabetes applying propensity scores to balance the groups. In study III and IV we utilized the 
Swedish Prescribed Drug Register to investigate adherence and non-adherence in 6,192 individuals 
with type 1 diabetes and novel users of LLT, in the context of CVD and socioeconomy.  
Results: Total-cholesterol to HDL-cholesterol ratio was a better predictor for cardiovascular risk in 
primary prevention than LDL-cholesterol, with a 12% elevated risk of CVD per 1 unit increase in the 
ratio. 
Individuals with type 1 diabetes and no history of CVD had a 22-44% lower risk of CVD and 
cardiovascular death when on LLT compared to the untreated individuals. High adherence to LLT 
was associated with a 22% lower risk of non-fatal CVD compared to lower adherence. Individuals 
discontinuing LLT within 18 months had a 43% higher risk of non-fatal CVD. Lower adherence was 
associated with male gender, young age, marital status and country of birth.  
Conclusion: The observational data from these presented studies emphasize the importance of 
regularly assessing and treating dyslipidemia in individuals with type 1 diabetes in order to achieve full 
cardioprotective treatment and lessen the cardiovascular burden in the type 1 diabetes population. 
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